# To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

> **NCT04024072** · PHASE3 · COMPLETED · sponsor: **Padagis LLC** · enrollment: 495 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** Brinzolamide 1% ophthalmic suspension
- **DRUG:** Azopt 1% Ophthalmic Suspension

## Key facts

- **NCT ID:** NCT04024072
- **Lead sponsor:** Padagis LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-24
- **Primary completion:** 2020-02-26
- **Final completion:** 2020-04-30
- **Target enrollment:** 495 (ACTUAL)
- **Last updated:** 2023-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04024072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04024072, "To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT04024072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*